If you’ve got fibromyalgia, there’s a good chance you’ve been handed a prescription for gabapentin at some point, usually with a line about calming down overactive nerves. Maybe it took the edge off. Maybe it did nothing at all. Maybe it left you foggy, a bit puffy round the ankles and no less sore than when you started. And maybe you went back, had the dose nudged up, and started the whole thing over again. That pattern is incredibly common, and it isn’t because you’ve done anything wrong. Gabapentin gets prescribed for fibromyalgia far more often than the evidence behind it would actually justify.
That gap is what this article is about. Gabapentin is one of the most widely prescribed drugs for widespread pain, and yet the research base for using it in fibromyalgia specifically is a lot thinner than almost anyone expects, thinner than the prescription rate and thinner than its reputation would ever let on. Read what the trials genuinely found, rather than what the packet implies, and the picture turns out to be a good deal more honest, and a good deal more useful to you.
So, this article does the reading for you. We’ll go through what gabapentin is, how it’s meant to work, and what the best available evidence actually shows for fibromyalgia, warts and all. We’ll look at why it gets handed out so freely when the guidelines are distinctly cool on it, the side effects and risks that rarely get a proper airing, and the honest question of where, if anywhere, it fits. If you want the wider view across every drug class, we’ve written a full breakdown of pain medication for hypermobility and EDS, and this is the fibromyalgia specific companion to it. It also sits alongside our broader guide to living with fibromyalgia, if you want the full picture of the condition.
A couple of things this article is not. It isn’t medical advice, and it certainly isn’t me telling you to stop a medication you’re on. If gabapentin genuinely helps you and the side effects are manageable, that’s a conversation for you and your prescriber, not for a blog post. It’s also not a pop at anyone who takes it. The aim is simply to give you the real evidence, so the next conversation with the person who writes your prescription is a better informed one.
So if you’re ready to see what the research genuinely says about gabapentin for fibromyalgia, rather than what just gets repeated, let’s get into it.
Why fibromyalgia pain doesn’t behave like ordinary pain
Before we get anywhere near the drug, it helps to understand why fibromyalgia pain is such an awkward target, because that’s the whole reason a nerve medication ends up borrowed for it in the first place. Most everyday pain is nociceptive. You stub your toe, specialised nerve endings detect the damage, they fire a signal up to the brain, and the brain produces pain so you stop doing the daft thing that caused it. It’s tidy, it makes sense, and it tends to respond reasonably well to standard painkillers.
Fibromyalgia pain is a different animal. The current understanding frames it as a condition of central sensitisation, which is a fancy way of saying the central nervous system has, over time, become more reactive to incoming signals than it should be [8]. The volume has been turned up. A signal that should barely register gets amplified into something loud and sore. It’s a bit like a smoke alarm that’s been recalibrated to go off the moment someone lights a candle. The alarm isn’t faulty, it’s doing exactly what it’s been set to do. The setting is just wrong.
This matters because the pain in central sensitisation doesn’t track tissue damage in any reliable way, which is a large part of why imaging so often comes back clear while you feel dreadful. It’s the same reason a single tablet rarely fixes everything, and it’s worth understanding the mechanics if you want the fuller story on what actually causes chronic pain in fibromyalgia and hypermobility, and on the amplified sensitivity we call hyperalgesia. Hold onto this picture, because it’s the key to why gabapentin does what it does, and why it can’t do more.
What gabapentin actually is, and how it’s meant to work
Gabapentin started life as an epilepsy drug, and it’s still licensed for seizures and, in many places, for neuropathic pain, the burning, shooting, electric sort you get with nerve damage. Fibromyalgia is nowhere on that licence, which is a detail we’ll come back to. And despite the name, it doesn’t actually act on GABA in the way the branding suggests.
What it does do is bind to a subunit of the voltage-gated calcium channels on nerve cells, the alpha-2-delta subunit, and by doing so it reduces the release of excitatory neurotransmitters from neurons that are firing too much [7]. In plain terms, it turns the gain down a little on an over-excited nervous system. On paper that sounds like exactly what you’d want for central sensitisation, where the whole problem is an over-excited system. In practice, as we’ll see, the results are a good deal more modest than the theory promises.
There’s a quirk worth knowing about too, because it changes how the drug behaves in the real world. Gabapentin is absorbed through a saturable transport system in the gut, which means its absorption is non-linear [6]. The higher the dose, the smaller the proportion your body actually takes up. Double the tablet and you don’t double the effect. That’s part of why people end up climbing the dose for diminishing returns, collecting side effects on the way up without much extra relief to show for it.
There’s a deeper mismatch worth understanding here, because it explains a lot. That alpha-2-delta subunit gabapentin targets becomes far more abundant after actual nerve injury, which is exactly the setting, neuropathic pain, where the drug has its best evidence [7]. Fibromyalgia isn’t a nerve-injury state. The pain is generated by altered processing in an intact nervous system, not by damaged nerves [8]. So the very target that gives gabapentin its foothold in neuropathic pain may simply be less relevant in fibromyalgia. The theory that it should calm central sensitisation is tidy, but the biology it leans on was worked out in a different kind of pain, and that gap between the two is a decent clue as to why the trial results have been so underwhelming.
What the evidence actually says
The single trial the whole thing rests on
The most rigorous look we have is the Cochrane review of gabapentin for fibromyalgia, and it found exactly one study that met its standard, a single trial with 150 participants in it [1]. Just the one. The reviewers rated the quality of that evidence as very low across every outcome, and their conclusion was about as blunt as Cochrane ever gets: there’s insufficient evidence to support or refute the suggestion that gabapentin reduces pain in fibromyalgia [1]. That’s not a ringing endorsement, and it isn’t a condemnation either. It’s an honest admission that we barely have the data to say.
The trial itself, run by Arnold and colleagues, tested gabapentin at 1200 to 2400mg a day over 12 weeks [2]. On the headline responder measure, 49 percent of people on gabapentin reported at least a 30 percent drop in pain, against 31 percent on placebo [1]. Read quickly, that looks like a win, but read it properly and it comes from a single small study rated very low quality, so it tells you what might be true rather than what is. And a placebo response of 31 percent is a reminder of how much movement you get in fibromyalgia trials from the sheer act of being in a trial at all. Withdrawals for side effects ran at 16 percent on the drug versus 9 percent on placebo [1], so a meaningful slice of people came off it because of how it made them feel, not because of what it did for their pain.
It’s worth being clear about why the evidence gets rated so low, because “very low quality” isn’t a throwaway insult. In the Cochrane grading system, a body of evidence starts high and gets marked down for things like having only one study, a small sample, a short follow-up, and no independent replication [1]. Gabapentin for fibromyalgia ticks nearly every one of those boxes. One trial, 150 people, twelve weeks, never repeated to the same standard. That isn’t enough to build a confident recommendation on, in either direction. It’s the difference between a single anecdote and a settled fact, and the honest thing is to treat it as the former.
Its licensed cousin tells you something
It’s worth putting gabapentin next to pregabalin, its close chemical relative, because the contrast is revealing. Pregabalin has been studied properly in fibromyalgia. The Cochrane review there pulled together eight studies and rated the evidence as high quality, a world away from gabapentin’s single low-quality trial [5]. And even with all that better evidence, the result is sobering: pregabalin at 300 to 600mg produces a worthwhile drop in pain for only about one person in ten more than placebo, with a number needed to treat somewhere in the range of 7 to 14 [5]. A meta-analysis that looked at both gabapentinoids in fibromyalgia landed in the same honest place, a limited benefit for a minority [3].
Sit with what that means for a second. The better-studied cousin, the one that regulators actually approved for fibromyalgia, still only helps a small minority above placebo. Gabapentin is the one with far weaker evidence again, and we’re extrapolating from a relative that isn’t exactly setting the world alight. So that’s a pretty shaky foundation for a drug prescribed as often as this one.
What the guidelines actually recommend
The European guidelines make the position clearer still. When EULAR revised its fibromyalgia recommendations, the only intervention to earn a strong recommendation of any kind was exercise [4]. Every drug that made the list got a weak recommendation at best. Pregabalin scraped in as a weak recommendation for use, agreed by 94 percent of the panel. Gabapentin didn’t even manage that. It was placed in the research-only category, with 100 percent agreement, meaning the experts felt the evidence supported studying it further rather than prescribing it as standard care [4]. For a drug this commonly dispensed, “research only” is a striking verdict, and it comes from the people who read all of this for a living.
None of this means nothing works. Where fibromyalgia does have better drug evidence, it tends to sit with the SNRIs like duloxetine, which have their own Cochrane review and a more convincing, if still modest, effect [11]. Amitriptyline has a long track record too, and we’ve looked at amitriptyline for fibromyalgia in its own right. The point isn’t that medication is pointless. It’s that gabapentin, specifically, is being asked to carry more weight than its evidence can bear.
So why is it prescribed so much?
If the evidence is this thin, the obvious question is why gabapentin keeps landing on so many prescriptions. Part of the answer is a category error. Fibromyalgia pain is nociplastic, driven by that turned-up central processing, but gabapentin’s real evidence home is neuropathic pain, where nerves are actually damaged [12]. Those are genuinely different problems, and a drug that helps one doesn’t automatically help the other. Because fibromyalgia pain can feel burning and nervy, and because gabapentin sits in the “nerve pain” mental drawer, it gets reached for almost by reflex.
The rest is ordinary clinical reality. It’s cheap, it’s familiar, and a prescriber under time pressure who wants to offer something has a limited menu. Handing over a trial of gabapentin feels like doing something, and sometimes it does help an individual, which keeps the habit alive. That’s understandable enough. It just isn’t the same as the evidence saying it works, and the two get quietly conflated in a ten-minute appointment.
Where gabapentin might still have a place
Being honest about weak evidence isn’t the same as writing a drug off entirely, and I’d rather give you the balanced version than a one-sided one. Fibromyalgia rarely turns up on its own. Plenty of people also have a genuine neuropathic component somewhere, a trapped nerve, a small-fibre problem, a diabetic neuropathy, and that’s the setting where gabapentin actually has decent evidence [12]. If a slice of your pain is truly nerve-damage pain sitting on top of the fibromyalgia, then a drug aimed at that mechanism is a more reasonable bet, and a thoughtful prescriber may be treating that layer rather than the fibromyalgia itself.
The same goes for the individual response. Averages hide a lot, and a treatment that does little across a whole trial population can still be the thing that helps one particular person sleep or take the edge off a bad patch. That’s a real effect for that person, and it counts. The trouble only starts when a reasonable trial in the right circumstances hardens into an automatic, open-ended prescription for everyone with widespread pain, handed out as though the evidence were strong. Used deliberately, for the right layer of the problem, gabapentin can earn a spot. Used by reflex, it mostly just collects side effects.
The side effects and risks that rarely make the conversation
If gabapentin were harmless, a low-odds punt might be fair enough. The trouble is the downsides get glossed over. The common ones are dizziness, drowsiness, swelling around the ankles from fluid retention, weight gain and a mental fuzziness that’s hard to tell apart from the fibro fog you already have [6]. For a condition where fatigue and cognitive trouble are already central complaints, a drug that adds to both is a hard sell, and weight gain has its own knock-on effects worth reading up on if you’re affected, which we’ve covered in fibromyalgia, weight gain and medication.
Then there’s dependence, which for years was brushed off as a non-issue and no longer is. Systematic reviews have documented genuine misuse, abuse and diversion of gabapentin and pregabalin, particularly among people who also use opioids [9][10]. This isn’t fringe stuff. In the UK, the concern was serious enough that from the 1st of April 2019 both drugs were reclassified as Class C controlled substances, tightening how they’re prescribed and dispensed, a decision that followed a national review of medicines linked to dependence and withdrawal [13]. Coming off gabapentin can bring its own withdrawal effects, which is exactly why stopping abruptly is a bad idea.
There’s a safety signal on breathing too, and it’s the sharpest edge of the lot. In December 2019 the US regulator warned that gabapentin and pregabalin can cause serious breathing problems, with the risk highest in older people, those with existing lung conditions, and anyone also taking central nervous system depressants such as opioids. That last point is the one to hold onto, because it stacks with the dependence data. The misuse that reviews have documented clusters precisely in people also taking opioids [9], and it’s the same combination that carries the breathing risk. If you’re on gabapentin alongside opioids, sedatives or other sleepy medication, that’s worth raising directly with your prescriber rather than leaving to chance.
The newest strand of the picture is cardiovascular, and it needs handling carefully. A 2024 study using a large health-records database followed 105,602 people with fibromyalgia and, after matching the groups on other risk factors, found that repeated gabapentin prescriptions were associated with a higher five-year risk of several cardiovascular events, including heart failure, with a hazard ratio of 1.27 [14]. A hazard ratio of 1.27 means the rate of new heart failure was about 27 percent higher in the gabapentin group over the follow-up, not that gabapentin raised any one person’s risk by that amount. And this is the crucial caveat: it’s an observational study, so it shows an association, not cause. People prescribed gabapentin repeatedly may simply be less well, less active or on more medication to begin with, and those differences are hard to fully iron out. It’s a reason to pay attention and to keep the risk-and-benefit sum honest, not a reason to panic.
If you’re already taking gabapentin
None of the above is a cue to tip your tablets down the sink. Some people genuinely do find gabapentin useful, and if you’re one of them, if it has meaningfully reduced your pain and you can live with the side effects, then it’s earning its place and this article changes nothing for you. Individual responses vary far more than any average, and the average is not you.
If you’re not sure whether it’s doing much, the useful thing is to give it a fair test rather than a vague one. An adequate trial is usually reckoned to be around 8 to 12 weeks at a proper therapeutic dose. If you’ve done that and honestly can’t point to a clear benefit, that’s worth taking back to your prescriber as a question rather than carrying on out of momentum. The right move might be to stay on it, to adjust it, or to taper off slowly and free up the space for something with better odds. What it shouldn’t be is an indefinite prescription nobody ever revisits. And whatever you decide, don’t stop it suddenly, because a gradual taper matters with this drug.
The elephant in the room
We can’t talk honestly about fibromyalgia medication without naming the thing that keeps outperforming all of it, and I make no apology for saying it plainly, because the evidence demands it. In the EULAR recommendations, the single strongest endorsement didn’t go to any drug. It went to exercise [4]. Across the better trials, appropriately graded movement produces improvements in pain, fatigue, sleep and function that tend to hold up beyond the short windows the drug studies run to.
I know how that reads when you’re in genuine pain, and it isn’t meant as the usual dismissive “just move more”. Given that fibromyalgia is a problem of a nervous system stuck on high alert, it makes sense that the interventions with the best track record are the ones that gradually retune that system rather than just muffling its signals. A drug can turn the volume down for a while. It can’t teach the system a new setting. That’s the bit that has to be trained, which is why we spend so much time on how to approach exercise for fibromyalgia without triggering a flare, why pacing matters so much, and why even something as simple as getting your movement outdoors can help.
That doesn’t make medication the enemy. Used with clear eyes, the right drug can lower the noise enough to let you do the work that actually shifts things, and there are options with more going for them than gabapentin, from the SNRIs to low-dose naltrexone and newer arrivals like TONMYA. The honest hierarchy just doesn’t put gabapentin near the top, and pretending otherwise doesn’t help you.
Frequently asked questions
Does gabapentin work for fibromyalgia?
For a minority of people it seems to help, but the evidence is genuinely weak. The one trial that met Cochrane’s standard, in 150 people, was rated very low quality, and the reviewers concluded there’s insufficient evidence to say whether gabapentin reduces fibromyalgia pain or not [1]. Some individuals do report benefit, which is real for them, but it isn’t backed by the kind of solid trial data you’d hope for.
Is gabapentin licensed for fibromyalgia?
No. Gabapentin isn’t approved for fibromyalgia by any major regulator. Its licence covers epilepsy and, in many countries, neuropathic pain. When it’s given for fibromyalgia it’s being used off-label, and the European guidelines place it in a research-only category rather than recommending it for routine care [4].
Gabapentin or pregabalin for fibromyalgia, which is better?
Pregabalin has the stronger evidence of the two, with eight high-quality studies behind it, though even then it only helps about one person in ten more than placebo [5]. Gabapentin rests on a single low-quality trial [1]. Neither is a magic bullet, and both carry a similar side-effect and dependence profile, so “better” here is a fairly low bar.
What dose is used, and how long should I try it?
The fibromyalgia trial used 1200 to 2400mg a day [2], though doses are always individualised by a prescriber. A fair test is usually around 8 to 12 weeks at a therapeutic dose. If there’s no clear benefit by then, it’s reasonable to review whether staying on it makes sense, rather than continuing indefinitely.
Can I just stop taking gabapentin?
Not abruptly. Gabapentin can cause withdrawal effects if it’s stopped suddenly, which is one reason it’s now a controlled drug in the UK [13]. If you want to come off it, do it as a planned, gradual taper with your prescriber rather than going cold turkey.
So, where does this leave us?
Gabapentin isn’t evil, and it isn’t useless. It’s a drug that got adopted for fibromyalgia on the strength of a hunch and a family resemblance to pregabalin, and the evidence never quite caught up with the prescribing. For a small number of people it helps, for a fair few it does very little, and it carries a side-effect and dependence profile that deserves more airtime than it usually gets. If it’s working for you, keep the conversation with your prescriber going and weigh it up honestly. If it isn’t, you’re not failing at anything, you’ve just been given a tool that was never a strong fit for the job.
The more useful message is the one that keeps holding up across all the honest evidence. The things that move the needle most in fibromyalgia are the ones that gradually retrain an over-sensitised nervous system, and no tablet does that for you. Medication can help you get to the start line. The work that changes things is the work you build from there, and if you want a map of what that looks like, our guide to living with fibromyalgia is the place to start.
— Adam —
References
[1] Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews. 2017. Art. No.: CD012188. doi: 10.1002/14651858.CD012188.pub2
[2] Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis & Rheumatism. 2007;56(4):1336-1344. doi: 10.1002/art.22457
[3] Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain. 2009;145(1):69-81. doi: 10.1016/j.pain.2009.05.014
[4] Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases. 2017;76(2):318-328. doi: 10.1136/annrheumdis-2016-209724
[5] Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews. 2016. Art. No.: CD011790. doi: 10.1002/14651858.CD011790.pub2
[6] Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. British Journal of Pain. 2020;14(2):104-114. doi: 10.1177/2049463720912496
[7] Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha-2-delta ligands: novel modulators of neurotransmission. Trends in Pharmacological Sciences. 2007;28(2):75-82. doi: 10.1016/j.tips.2006.12.006
[8] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030
[9] Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi: 10.1007/s40265-017-0700-x
[10] Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174. doi: 10.1111/add.13324
[11] Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database of Systematic Reviews. 2018. Art. No.: CD010292. doi: 10.1002/14651858.CD010292.pub2
[12] Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology. 2015;14(2):162-173. doi: 10.1016/S1474-4422(14)70251-0
[13] Marsden J, White M, Annand F, et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. The Lancet Psychiatry. 2019;6(11):935-950. doi: 10.1016/S2215-0366(19)30331-1
[14] Pan Y, Blankfield RP, Kaelber DC, Xu R. Association of adverse cardiovascular events with gabapentin and pregabalin among patients with fibromyalgia. PLOS ONE. 2024;19(7):e0307515. doi: 10.1371/journal.pone.0307515
